文献速递血栓与止血

Caravaggio研究中癌症患者偶发性静脉血栓栓塞的临床特征与结局

Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
PubMed 文献 · J Thromb Haemost · 2021-07-29

偶发性VTE患者以肺栓塞、结直肠癌、ECOG评分0分及局部晚期或转移性癌更常见;其复发VTE发生率数值上更低(4.3% vs 7.4%,HR 0.57,95%CI 0.29-1.10),大出血发生率数值上更高(5.2% vs 3.6%,HR 1.43,95%CI 0.74-2.77)。阿哌沙班与达肝素在两类患者中的相对疗效与安全性无显著差异。

要点

  • 偶发性VTE患者肺栓塞、结直肠癌、ECOG 0分及晚期癌更常见。
  • 偶发性VTE复发率数值低于症状性VTE(4.3% vs 7.4%),大出血率数值更高(5.2% vs 3.6%)。
  • 阿哌沙班与达肝素在偶发性和症状性VTE中的相对疗效与安全性无显著差异。

核心结论

  • 与症状性VTE相比,偶发性VTE患者就诊时临床特征不同,复发VTE发生率数值上更低,大出血发生率数值上更高。

研究设计与样本

  • Caravaggio研究的预设亚组分析,比较阿哌沙班与达肝素治疗癌症相关VTE 6个月。

主要发现

  • 偶发性VTE患者中肺栓塞伴或不伴深静脉血栓、结直肠癌、ECOG评分0分、局部晚期或转移性癌更常见。
  • 症状性VTE患者中深静脉血栓、血液系统肿瘤、ECOG评分2分更常见。
  • 偶发性VTE复发10例(4.3%),症状性VTE复发68例(7.4%),HR 0.57(95%CI 0.29-1.10)。
  • 偶发性VTE大出血12例(5.2%),症状性VTE大出血33例(3.6%),HR 1.43(95%CI 0.74-2.77)。

关键数值与推荐

  • 偶发性VTE复发HR 0.57(95%CI 0.29-1.10),大出血HR 1.43(95%CI 0.74-2.77)。
  • 症状性VTE中阿哌沙班对比达肝素复发HR 0.73(95%CI 0.45-1.19),大出血HR 0.93(95%CI 0.47-1.83)。
  • 偶发性VTE中阿哌沙班对比达肝素复发HR 0.41(95%CI 0.11-1.56),大出血HR 0.96(95%CI 0.31-2.96)。

临床怎么用

  • 偶发性VTE与症状性VTE临床特征不同,抗凝治疗选择可参考Caravaggio研究亚组结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical guidelines advise similar anticoagulant treatment for symptomatic and incidental cancer-associated venous thromboembolism (VTE). We investigated clinical features and outcomes of cancer patients with incidental or symptomatic VTE randomized in the Caravaggio study. OBJECTIVES: We performed a predefined sub-analysis of the Caravaggio study in order to investigate the clinical features and outcomes of incidental and symptomatic VTE in patients with cancer. The relative efficacy and safety of apixaban and dalteparin in patients with incidental and symptomatic VTE was also assessed. METHODS: The Caravaggio study compared apixaban to dalteparin for the 6-month treatment of cancer-associated VTE. The primary efficacy and safety outcomes were recurrent VTE and major bleeding. RESULTS: Two hundred thirty patients (20%) had incidental and 925 (80%) symptomatic VTE. Pulmonary embolism with or without deep vein thrombosis as index event, colorectal cancer, Eastern Cooperative Oncology Group (ECOG) score of 0, and locally advanced or metastatic cancer were more frequent in patients with incidental VTE. Deep vein thrombosis as index event, hematological cancer, and ECOG score of 2 were more frequent in patients with symptomatic VTE. Ten patients (4.3%) with incidental and 68 (7.4%) with symptomatic VTE had recurrent VTE (hazard ratio [HR] 0.57, 95% confidence interval [CI] 0.29-1.10). Major bleeding occurred in 12 (5.2%) patients with incidental VTE and in 33 (3.6%) patients with symptomatic VTE (HR 1.43, 95% CI 0.74-2.77). When comparing apixaban to dalteparin in patients with symptomatic and incidental VTE, the HR for recurrence was 0.73 (95% CI 0.45-1.19) and 0.41 (95% CI 0.11-1.56), respectively, and the HR for major bleeding 0.93 (95% CI 0.47-1.83) and 0.96 (95% CI 0.31-2.96), respectively. CONCLUSIONS: Compared to cancer patients with symptomatic VTE, those with incidental VTE have different clinical features at presentation, with a numerically lower incidence of recurrent VTE and a numerically higher incidence of major bleeding.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Giustozzi M, Connors JM, Ruperez Blanco AB, et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. J Thromb Haemost. 2021. PMID: 34260816. doi:10.1111/jth.15461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。